Compare Abbott Laboratories (ABT) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Tencent Music Entertainment Group - ADR — how do they compare? Abbott Laboratories trades at $110.99 (market cap $187.95B), while Tencent Music Entertainment Group - ADR trades at $8.43 (market cap $16.09B). The key difference: Abbott Laboratories is far larger — about 11.7× Tencent Music Entertainment Group - ADR's market cap, and Tencent Music Entertainment Group - ADR pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| ABT | TME | |
|---|---|---|
Market Cap | $187.95B | $16.09B |
Sector | Health | Media |
52-Week High | $136.62 | $26.36 |
52-Week Low | $82.57 | $8.16 |
Enterprise Value | $214.96B | $14.05B |
Dividend Yield | 2.32% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Tencent Music Entertainment (TME) is trading at $8.38, down 15.35% amid mixed Q2 2026 results that showed revenue growth but profit beat expectations. The stock faces bearish technical signals with oversold RSI conditions, while fundamentals remain strong with 33.6% net margin and attractive valuation at 10.29 P/E. Recent news highlights slowing operational growth and competitive pressures, though institutional activity shows mixed positioning with some funds increasing stakes while others reduce exposure.
TME presents a value opportunity with solid profitability and cash flow generation, but near-term headwinds include intensifying competition, AI-related copyright challenges, and slowing user growth. Analyst consensus leans neutral with 45.8% buy ratings, suggesting cautious optimism for long-term investors willing to navigate current volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
